LOXO-101: Interim Phase Ia data

Interim data from 15 patients with advanced solid tumors in the Phase Ia portion of an open-label, dose-escalation, U.S. Phase Ia/Ib trial showed that once-daily 50 and 100 mg and twice-daily 100 mg o...